InterMune (NASDAQ: ITMN) announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis (IPF). ASCEND is a multinational, randomized, double-blind, placebo controlled Phase 3 trial designed to evaluate the safety and efficacy of Esbriet® (pirfenidone) in IPF patients with mild to moderate impairment in lung function. The primary endpoint is lung function, as measured by change in forced vital capacity (FVC) from baseline to Week 52... ![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2FjarUS_woHQpxSwv2NZ-E9XmPet8%2F0%2Fdi&hash=647b58af64af52cc82e16cf17e07dc97)
![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2FjarUS_woHQpxSwv2NZ-E9XmPet8%2F1%2Fdi&hash=a8f1eb05a945b55ec2854db419d0510f)
More...
More...